Janus Henderson Group PLC Acquires 273,670 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Janus Henderson Group PLC lifted its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 40.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 949,334 shares of the company's stock after acquiring an additional 273,670 shares during the period. Janus Henderson Group PLC owned approximately 3.21% of Dianthus Therapeutics worth $25,936,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the company. Great Point Partners LLC lifted its stake in Dianthus Therapeutics by 21.3% during the 2nd quarter. Great Point Partners LLC now owns 757,929 shares of the company's stock valued at $19,615,000 after acquiring an additional 132,929 shares during the period. Vanguard Group Inc. raised its holdings in shares of Dianthus Therapeutics by 250.0% during the first quarter. Vanguard Group Inc. now owns 537,828 shares of the company's stock valued at $16,135,000 after purchasing an additional 384,182 shares during the last quarter. Braidwell LP lifted its position in Dianthus Therapeutics by 34.6% during the third quarter. Braidwell LP now owns 493,687 shares of the company's stock valued at $13,517,000 after purchasing an additional 126,836 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Dianthus Therapeutics by 142.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company's stock worth $4,543,000 after purchasing an additional 97,362 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in Dianthus Therapeutics by 860.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company's stock worth $2,095,000 after purchasing an additional 72,509 shares during the period. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Price Performance

Shares of DNTH stock traded up $0.73 during trading hours on Friday, reaching $24.39. 167,938 shares of the company traded hands, compared to its average volume of 341,741. The firm has a 50-day moving average price of $26.44 and a 200 day moving average price of $26.49. The company has a market cap of $721.94 million, a P/E ratio of -9.76 and a beta of 1.74. Dianthus Therapeutics, Inc. has a 12-month low of $6.58 and a 12-month high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.15). The firm had revenue of $2.17 million for the quarter, compared to analysts' expectations of $1.07 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. Sell-side analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on DNTH. Wedbush dropped their price target on Dianthus Therapeutics from $38.00 to $36.00 and set an "outperform" rating on the stock in a research note on Friday, August 9th. Oppenheimer increased their target price on Dianthus Therapeutics from $48.00 to $52.00 and gave the company an "outperform" rating in a report on Monday, November 11th. Raymond James boosted their price target on Dianthus Therapeutics from $51.00 to $56.00 and gave the company an "outperform" rating in a research note on Friday, November 8th. Finally, HC Wainwright reiterated a "buy" rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $46.43.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.